Martin Eduardo Gutierrez MD
Director Drug Discovery/Phase I Research Chief of Thoracic Oncology Member of GI Division
Join to View Full Profile
92 2nd StHackensack, NJ 07601
Phone+1 551-996-5863
Fax+1 551-996-0580
Dr. Gutierrez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
Pontifical Xavierian UniversityClass of 1991
Certifications & Licensure
NY State Medical License 2021 - 2028
DC State Medical License 2024 - 2027
NJ State Medical License 2011 - 2027
FL State Medical License 2000 - 2014
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum Start of enrollment: 2009 Mar 01
- Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Start of enrollment: 2014 Feb 01
- A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Publications & Presentations
PubMed
- Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 ...Melissa L Johnson, Manish R Patel, Gerald S Falchook, Takafumi Koyama, Martin Gutierrez
The Lancet. Oncology. 2026-04-01 - A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Brinda Alagesan, Anna M Varghese, Celina Ang, Martin Gutierrez, Moshe Kamar
Clinical Cancer Research. 2026-03-16 - "A lot of the times, patients really don't know what questions to ask:" Communication perspectives of Black patients with advanced lung cancer.Katarina E AuBuchon, Ayomide Aduloju, Osairys M Billini, Amanda Khoudary, Jennifer D Rodriguez
Patient Education and Counseling. 2026-03-03
Lectures
- Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Press Mentions
Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022- Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021
- NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
